Last reviewed · How we verify
NCT06654999
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
trial testing Deep Ensemble for the Recognition of Malignancy (DERM) in Skin Cancer in 115 participants. Completed in 30 June 2025.
30 June 2025
Quick facts
| Lead sponsor | Skin Analytics Limited |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 115 |
| Start date | 18 December 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- Deep Ensemble for the Recognition of Malignancy (DERM)
Conditions studied
- Skin Cancer — all drugs for Skin Cancer →
- Melanoma of Skin — all drugs for Melanoma of Skin →
- Squamous Cell Cancer — all drugs for Squamous Cell Cancer →
- Basal Cell Cancer — all drugs for Basal Cell Cancer →
Sponsor
Skin Analytics Limited
Who can join
18 and older, any sex, with Skin Cancer or Melanoma of Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
DERM is a Medical Device that uses artificial intelligence to help doctors check if a skin lesion might be cancerous. It works by analysing close-up pictures of skin lesions taken with a smartphone. This study aims to demonstrate how consistent (precise) the output of DERM is: i.e. does it provide the same result when it analyses multiple photos of the same lesion (repeatability), and when the same lesion is photographed by different people, or with different cameras (reproducibility). Adults with at least one skin lesion that doctors are checking for cancer, as part of their standard care, will be able to take part. Suitable lesions will be photographed three times, each by three different people using three sets of image capture hardware (specifically, an iPhone 11 with a DL200/HR dermoscopic lens). Each image will be checked for good image quality as it is captured. Images will then be transferred to DERM, where they'll be analysed. The DERM output won't be shared with the patients or doctors involved in the study. The patients will continue to have their skin lesion biopsy/excised, in accordance with standard of care. Their diagnosis will be collected and compared to the output from DERM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06654999
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Deep Ensemble for the Recognition of Malignancy (DERM)
Trials testing the same drug.
- NCT05126173 — DERM US and EU Validation Study · completed
- NCT04116983 — DERM NMSC Validation Study · completed
- NCT04123678 — DERM Health Economics Study · completed
Other recruiting trials for Skin Cancer
Currently open trials in the same condition.
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
- NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
- NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting
Other Skin Analytics Limited trials
Trials by the same sponsor.
- NCT05126173 — DERM US and EU Validation Study · completed
- NCT04116983 — DERM NMSC Validation Study · completed
- NCT04123678 — DERM Health Economics Study · completed
- NCT02612168 — Melanoma Image Analysis Algorithm (MIAA) Validation Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06654999 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Skin Analytics Limited
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06654999.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing